Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci (2015) 1.53

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm (2015) 1.09

Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07

Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci (2015) 0.96

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91

Human Aquaporin-4 and Molecular Modeling: Historical Perspective and View to the Future. Int J Mol Sci (2016) 0.88

Applying complement therapeutics to rare diseases. Clin Immunol (2015) 0.87

Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology (Berl) (2015) 0.82

Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation (2016) 0.81

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf (2015) 0.80

Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. Mediators Inflamm (2016) 0.79

Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica. J Neuroinflammation (2016) 0.79

NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. J Neuroinflammation (2015) 0.78

Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord. PLoS One (2016) 0.78

Mechanisms of Autoantibody-Induced Pathology. Front Immunol (2017) 0.76

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol (2014) 0.76

Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. J Neuroinflammation (2016) 0.76

Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. Acta Neuropathol Commun (2016) 0.76

Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun (2017) 0.75

Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies. Int J Mol Sci (2016) 0.75

Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases. Neural Regen Res (2016) 0.75

Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica. BMC Neurol (2016) 0.75

Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases. Int J Clin Exp Pathol (2015) 0.75

Accuracy of the Fluorescence-Activated Cell Sorting Assay for the Aquaporin-4 Antibody (AQP4-Ab): Comparison with the Commercial AQP4-Ab Assay Kit. PLoS One (2016) 0.75

Determining the Spatial Relationship of Membrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy. Biophys J (2017) 0.75

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report. Neurol Neuroimmunol Neuroinflamm (2017) 0.75

Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission. Front Neurosci (2017) 0.75

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO). J Neuroinflammation (2016) 0.75

Neuromyelitis Optica Masquerading as Lumbosacral Radiculopathy: A Case Report. Ann Rehabil Med (2016) 0.75

Increased Circulating T Follicular Helper Cells Are Inhibited by Rituximab in Neuromyelitis Optica Spectrum Disorder. Front Neurol (2017) 0.75

Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler (2015) 0.75

Hypersensitivity Responses in the Central Nervous System. Front Immunol (2015) 0.75

Comparative Molecular Dynamics Study of Neuromyelitis Optica-Immunoglobulin G Binding to Aquaporin-4 Extracellular Domains. Biochim Biophys Acta (2017) 0.75

The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. Front Immunol (2017) 0.75

Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD. J Neurol (2016) 0.75

Aquaporin-Targeted Therapeutics: State-of-the-Field. Adv Exp Med Biol (2017) 0.75

The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis. Biochem Biophys Rep (2016) 0.75

Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun (2017) 0.75

Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology (2014) 6.73

Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci (2004) 5.70

Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol (2014) 4.69

Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol (2010) 4.50

Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 4.39

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95

Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology (2010) 3.34

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol (2009) 3.26

Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24

The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13

Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med (2012) 3.12

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12

An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96

Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol (2011) 2.83

Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46

Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol (2012) 2.45

Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40

EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J (2001) 2.38

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35

Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler (2011) 2.30

Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26

Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci (2009) 2.24

Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12

Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11

CNS aquaporin-4 autoimmunity in children. Neurology (2008) 2.10

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99

Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J Biol Chem (2011) 1.98

Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain (2007) 1.93

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86

ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun (1991) 1.85

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology (2011) 1.75

Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol (2012) 1.75

Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology (2007) 1.74

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler (2012) 1.73

Complement in human diseases: Lessons from complement deficiencies. Mol Immunol (2009) 1.73

Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol (2011) 1.72

A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology (2007) 1.70

Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol (2010) 1.66

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65

Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63

Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol (2006) 1.63

Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord (2012) 1.62

Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol (2011) 1.61

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A (2011) 1.60

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60

Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58

A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58

Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem (2012) 1.55

Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler (2012) 1.54

Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54

Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci (2006) 1.52

Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci (2011) 1.49

Neuromyelitis optica and pregnancy. Neurology (2012) 1.49

Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev (2011) 1.45

Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42

Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler (2009) 1.41

Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol (2013) 1.40

Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler (2011) 1.36

Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol (2010) 1.35

Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry (2011) 1.32

Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo. J Immunol (2004) 1.31

Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31

An epidemiological study of neuromyelitis optica in Cuba. J Neurol (2009) 1.30

MS and neuromyelitis optica in Martinique (French West Indies). Neurology (2001) 1.30

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol (2013) 1.30

Corticosteroids: the drugs to beat. Eur J Pharmacol (2006) 1.29

Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (2012) 1.28

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol (2014) 1.27

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27

Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler (2012) 1.26

Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med (2010) 1.25

CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.24

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23

Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci (2011) 1.20

Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem (2011) 1.20

Ontogeny of water transport in rat brain: postnatal expression of the aquaporin-4 water channel. Eur J Neurosci (1999) 1.20

Progress and Trends in Complement Therapeutics. Adv Exp Med Biol (2013) 1.20

Meningococcal disease and the complement system. Virulence (2013) 1.19

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler (2011) 1.19

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol (2012) 1.17

Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler (2009) 1.15

Familial neuromyelitis optica. Neurology (2010) 1.14